healthUpdated: Jul 23, 2020 01:04 ISTGlenmark’s favipiravir hastens recovery among mild to moderate coronavirus disease (Covid-19) cases, the pharma major said as it announced results of its phase III clinical trials on Wednesday. “…40% faster achievement of clinical cure defined as the physician’s assessment of normalization of clinical signs – temperature, oxygen saturation, respiratory rate and cough with a statistically significant reduction in median time to clinical cure in the Favipiravir treatment arm (3 days)…, compared to the control arm (5 days)….”, the statement said. Favipiravir is a broad-spectrum oral antiviral drug that inhibits the Sars-Cov-2 virus, which causes Covid-19, from replicating. Click here for the complete coverage of the Covid-19 pandemicThe India trials were conducted on 150 patients across seven clinical sites in India. The open-label randomized, multicenter clinical trial, evaluated the efficacy and safety of favipiravir plus standard supportive care (favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate cases.

Source: Hindustan Times July 22, 2020 19:35 UTC